Skip to main content

GSK buys out Novartis in $13 billion consumer healthcare shake-up

By April 2, 2018News
GlaxoSmithKline-gsk-logo

GlaxoSmithKline-gsk-logo

GlaxoSmithKline (GSK.L) is buying Novartis (NOVN.S) out of their consumer healthcare joint venture for $13 billion, taking full control of products including Sensodyne toothpaste, Panadol headache tablets, muscle gel Voltaren, and Nicotinell patches.

{iframe}https://www.reuters.com/article/us-novartis-gsk/gsk-buys-out-novartis-in-13-billion-consumer-healthcare-shake-up-idUSKBN1H30FK{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.